Core Viewpoint - Haixi New Drug (02637) experienced a significant stock price increase, rising over 7% in early trading and currently up by 5.87%, with a market capitalization exceeding HKD 11 billion [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has 15 approved generic drug products covering various therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting cancer, ophthalmology, and respiratory diseases [1] Market Performance - The current average daily market capitalization of Haixi New Drug is HKD 9.94 billion, which exceeds the threshold requirement for Hong Kong Stock Connect [1]
海西新药早盘一度涨超7% 总市值现突破110亿港元